Conclusions
weight loss
In conclusion, 24 weeks of liraglutide, 3.0 mg, as an adjunct to a lifestyle intervention in people with poor weight loss and a suboptimal GLP-1 response after metabolic surgery, was safe and well tolerated and led to clinically meaningful reductions in body weight. Our findings therefore suggest that liraglutide, 3.0 mg, may have a role in the treatment of people with poor weight loss following metabolic surgery.